LTA and graft versus host disease: To determine whether depletion of LT-expressing cells in the xenogeneic Hu-SCID model of GVHD would also achieve therapeutic benefit, we generated a fully humanized anti-LT-α antibody, designated MLTA3698A, selected for its ability to bind LT-α in its different trimeric forms and to mediate depletion of LT-α-expressing cells.